NASDAQ · DMRA
Damora Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DMRA: Nov 5, 2026
Damora Therapeutics, Inc. Ordinary Shares is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.52. The reported EPS for the same quarter last year was $-2.36.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.52 | $-0.37 | $-0.70 | 3 |
| Dec 2026 | $-0.49 | $-0.38 | $-0.56 | 3 |
| Mar 2027 | $-0.48 | $-0.38 | $-0.59 | 2 |
| Jun 2027 | $-0.50 | $-0.39 | $-0.61 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Fintel · Zacks- RTTNews · Sep 3, 8:33 AM EDTDamora Therapeutics Grants Inducement Awards To Three New Employees(RTTNews) – Damora Therapeutics, Inc. (DMRA), a biotechnology company developing therapies for hematologic disorders, announced that it granted equity awards to three newly hired, non-executive employees.
- RTTNews · Aug 11, 7:03 AM EDTDamora Posts Wider Loss In Q2 On Increased Expenses; Expects Cash Runway Into 2029(RTTNews) – Damora Therapeutics, Inc. (DMRA) announced financial results for the second quarter ended June 30, 2026, reporting a higher loss, primarily driven lower by operating expenses that more than doubled from last year.
- The Motley Fool · May 30, 2:12 PM EDTWhy This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% SurgeFCPM III Services B.V. initiated a new position in Damora Therapeutics, adding 2,441,000 shares last quarter; the estimated trade size was $65.63 million (quarterly average pricing).
- Fintel · May 28, 8:03 PM EDTWedbush Initiates Coverage of Damora Therapeutics (DMRA) with Outperform RecommendationFintel reports that on May 28, 2026, Wedbush initiated coverage of Damora Therapeutics (NasdaqCM:DMRA) with a Outperform recommendation. Analyst Price Forecast Suggests 82.75% Upside
- Zacks · Apr 20, 12:00 PM EDTWhat Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Apr 10, 9:55 AM EDTHow Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- RTTNews · Mar 20, 7:50 AM EDTDamora Therapeutics Posts FY25 Results, Advances MutCALR Blood-Disorder Pipeline(RTTNews) – Damora Therapeutics, Inc. (DMRA) reported full-year 2025 results and highlighted progress across its pipeline of therapies targeting mutant calreticulin (mutCALR)-driven blood disorders, including essential thrombocythemia and myelofibrosis.
- Fintel · Feb 17, 4:02 PM ESTUBS Initiates Coverage of Galecto (GLTO) with Buy RecommendationFintel reports that on February 17, 2026, UBS initiated coverage of Galecto (NasdaqCM:GLTO) with a Buy recommendation. Analyst Price Forecast Suggests 42.45% Upside
- RTTNews · Feb 11, 5:59 AM ESTGalecto Prices $275 Mln Public Offering At $19 Per Share, Stock Down(RTTNews) – Galecto, Inc. (GLTO), a clinical-stage biotechnology company, announced the pricing of its previously announced public offering of 14.47 million shares at $19.00 per share. The gross proceeds are expected to be approximately $275 million.
- Fintel · Jan 14, 3:57 PM ESTGalecto (GLTO) Price Target Increased by 13.89% to 41.82The average one-year price target for Galecto (NasdaqCM:GLTO) has been revised to $41.82 / share. This is an increase of 13.89% from the prior estimate of $36.72 dated December 18, 2025. The price target is an average of many targets provided by analysts. The
- Fintel · Jan 7, 7:03 PM ESTLeerink Partners Initiates Coverage of Galecto (GLTO) with Outperform RecommendationFintel reports that on January 7, 2026, Leerink Partners initiated coverage of Galecto (NasdaqCM:GLTO) with a Outperform recommendation. Analyst Price Forecast Suggests 68.13% Upside
- Fintel · Dec 21, 4:25 AM ESTGalecto (GLTO) Price Target Increased by 12.50% to 36.72The average one-year price target for Galecto (NasdaqCM:GLTO) has been revised to $36.72 / share. This is an increase of 12.50% from the prior estimate of $32.64 dated December 3, 2025. The price target is an average of many targets provided by analysts. The l
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Damora Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.